Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Abbott Laboratories for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Abbott Laboratories (ABT)


Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
3 months ended Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net earnings (loss)
Depreciation
Amortization of intangible assets
Share-based compensation
Impact of currency devaluation
Amortization of inventory step-up
Gain on sale of businesses
Mylan N.V. equity investment adjustment
Gain on sale of Mylan N.V. shares
Net loss on extinguishment of debt
Trade receivables
Inventories
Other, net
Adjustments to reconcile net earnings (loss) to net cash from (used in) operating activities
Net cash from (used in) operating activities
Acquisitions of property and equipment
Acquisitions of businesses and technologies, net of cash acquired
Proceeds from business dispositions
Proceeds from the sale of Mylan N.V. shares
(Purchases) sales of other investment securities, net
Other
Net cash (used in) from investing activities
Net borrowings (repayments) of short-term debt and other
Proceeds from the issuance of long-term debt
Repayments of long-term debt
Payment of bridge financing fees
Purchase of Alere preferred stock
Payment of contingent consideration
Purchases of common shares
Proceeds from stock options exercised
Dividends paid
Net cash from (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-06), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-07).

Cash flow statement item Description The company
Net cash from (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories’s net cash from (used in) operating activities increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Net cash (used in) from investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories’s net cash (used in) from investing activities decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
Net cash from (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories’s net cash from (used in) financing activities increased from Q1 2019 to Q2 2019 but then slightly decreased from Q2 2019 to Q3 2019.